How do CH50 and AH50 assays differ from component quantification? Essential Raw Material & Workflow Guide

The complement system acts as a sentinel of innate immunity, but diagnosing its dysfunction requires two distinct types of laboratory tests. CH50 and AH50 assays measure the overall functional lytic activity of the entire classical and alternative complement pathways, from initiation to membrane attack complex formation. In contrast, specific component quantification—using methods like nephelometry, ELISA, or radial immunodiffusion—measures the antigenic mass of individual complement proteins, such as C3 or C4, without assessing their biological activity. In a diagnostic workflow, functional screening comes first, and subsequent quantitative reflex testing isolates the precise molecular defect.

The fundamental difference is function versus mass. Functional assays (CH50/AH50) tell you whether the complement cascade works; quantitative component assays tell you how much of a specific protein is present. A complete evaluation combines both: screen for pathway integrity with hemolytic tests, then pinpoint the deficient component with immunoassays—provided you have the right raw materials to formulate each with consistent performance.

The Two-Tier Diagnostic Approach: Functional vs. Quantitative Testing

CH50 and AH50: Measuring the Whole Orchestra

A CH50 assay evaluates the classical pathway by measuring the serum volume required to lyse 50% of antibody-sensitized sheep red blood cells (SRBCs). This process depends on the sequential activation of all nine complement proteins (C1–C9). If any component is missing or non-functional, lysis is impaired, yielding a low CH50 value.

The AH50 assay targets the alternative pathway using rabbit red blood cells or specific activating surfaces that trigger spontaneous C3 tick-over. It requires a functional set of alternative pathway factors: Factor B, Factor D, properdin, Factors H and I, along with the terminal pathway components C5–C9. The assay buffer contains Mg‑EGTA to chelate calcium and block the classical pathway, ensuring alternative pathway specificity.

Both assays are functional screens—they measure the cascade’s end result (cell lysis) and therefore reflect the biological activity of every component in the pathway. If the orchestra fails to play, you hear silence; the CH50 tells you the ensemble isn’t working.

Specific Component Quantification: Isolating the Soloist

When a functional defect is detected, the next step is to quantify individual complement proteins. Techniques like rate nephelometry, turbidimetry, radial immunodiffusion (RID), and ELISA use high-affinity antibodies to measure the concentration (mass) of C3, C4, C1q, Factor B, and other components.

These antigenic assays are fast, automatable, and highly reproducible, making them ideal for tracking complement consumption in diseases like systemic lupus erythematosus. However, they have a critical limitation: they detect protein mass, not function. A mutated C4 molecule may be present at normal levels but enzymatically dead, and only functional testing would catch the deficiency.

The Diagnostic Workflow: From Screening to Pinpointing Defects

Step 1: Screen with CH50 and AH50

The first question is whether the complement system can mount a full hemolytic attack. A normal CH50 and AH50 essentially rules out a major complement deficiency. Abnormal results trigger a reflex pathway.

Step 2: Pattern Interpretation and Reflex Testing

The combination of results pinpoints the location of the defect:

• Low CH50 with normal AH50 → defect exclusively in the classical pathway’s early components: C1 (C1q, C1r, C1s), C4, or C2.
• Low AH50 with normal CH50 → defect in the alternative pathway’s unique factors: Factor B, Factor D, or properdin.
• Both low → defect in components shared by both pathways, typically C3, or the terminal pathway C5–C9.

Once the pattern narrows the suspect list, specific immunoassays for those candidates confirm the exact deficiency. For example, a low CH50/normal AH50 pattern prompts measurement of C4 and C2 antigen levels using validated nephelometric or ELISA kits.

Why Activity Matters More Than Mass

A protein may be immunologically detectable but functionally inert due to a missense mutation. A patient with a dysfunctional C1q mutation can have normal C1q protein levels by ELISA but zero classical pathway activity. Functional assays are non-negotiable for detecting such genetically inactive proteins; quantitative assays alone would produce a false-negative diagnosis.

Raw Materials for Assay Formulation

Building these assays in an IVD or clinical lab environment demands a suite of high‑purity, stable raw materials to guarantee sensitivity and lot‑to‑lot consistency.

CH50 Assay Requirements

• Sheep red blood cells (SRBCs): Must be fresh, stabilized, and free of hemolysis.
• Rabbit hemolysin (anti‑SRBC antibody): Used to sensitize SRBCs; critical for classical pathway activation.
• Gelatin veronal buffer with Ca²⁺ and Mg²⁺: Maintains osmotic conditions and supplies the divalent cations essential for C1 complex assembly.
• Patient serum: Must be handled carefully—serum is preferred over plasma, and it must be processed and stored at −80°C to preserve complement activity.
• Validated calibrators and complement‑depleted sera: Provide reference values and allow for controls that confirm lysis is complement‑dependent.

AH50 Assay Requirements

• Rabbit red blood cells: These naturally activate the human alternative pathway.
• Mg‑EGTA buffer: Chelates calcium to block the classical pathway while allowing magnesium‑dependent alternative pathway activation.
• Purified alternative pathway factor controls (Factor B, Factor D, properdin): Essential for validating assay specificity and troubleshooting.
• Standardized reference sera: For calibration of 50% lysis point.

Specific Component Immunoassay Materials

• High‑affinity polyclonal or monoclonal antibodies: Targeting C3, C4, C1q, C2, Factor B, or activation fragments like C3a and C5a.
• Purified complement proteins: Used as calibrators and standards to establish quantitative curves. These must be fully functional and free of degradation products.
• Complement‑depleted and normal‑range control sera: To validate assay accuracy and detect interfering factors.
• Detection reagents: Enzyme conjugates for ELISA, polystyrene particles for turbidimetric assays, or fluorophores—all requiring strict quality control.

Critical Raw Material Quality Considerations

All cell‑based reagents must show no spontaneous lysis and maintain consistent antigenicity across lots. Protein reagents must be endotoxin‑free and properly folded, as denatured proteins lead to inaccurate calibration. For manufacturing robust kits, lot‑to‑lot validation of hemolysin titre, red blood cell fragility, and antibody specificity is essential.

Understanding the Trade‑offs

Pre‑analytical Sensitivity of Functional Assays

CH50 and AH50 are exquisitely sensitive to sample handling. Delays in processing, repeated freeze‑thaw cycles, or heat exposure destroy complement activity, yielding misleadingly low results. Laboratories must enforce strict cold‑chain protocols.

Quantitative Assays: Concentration, Not Competence

A normal C3 level by nephelometry tells you nothing about whether that C3 molecule can participate in convertase formation. In diseases with normal protein synthesis but dysfunctional proteins, quantitative assays alone miss the diagnosis.

Throughput and Labor

Functional hemolytic assays are manual, low‑throughput, and time‑sensitive, requiring fresh red blood cells and precise incubation steps. In contrast, automated nephelometry or ELISA platforms process hundreds of samples per day with minimal hands‑on time—a significant advantage for high‑volume clinical settings.

Cost of Comprehensive Testing

While functional screening is cheap in reagent terms, the reflex to specific component assays increases total cost. A well‑designed panel balances the need for functional insight with the practicality of automated protein measurement, often deploying functional tests only when suspicion of genetic deficiency is high.

Making the Right Choice for Your Diagnostic Goal

Align your assay selection and raw material sourcing with the clinical question you need to answer.

• If your primary focus is broad deficiency screening: Start with CH50 and AH50 to test total pathway integrity. Enforce rigorous serum collection and storage protocols to avoid false‑negative functional results.
• If your primary focus is monitoring immune complex disease activity (e.g., SLE): Use quantitative C3 and C4 assays by nephelometry; they provide rapid, reproducible measures of complement consumption that correlate with disease flares.
• If your primary focus is pinpointing a molecular defect identified by functional screening: Deploy specific antigenic assays with validated antibodies and calibrators against the suspect protein (C1q, C2, C4, Factor B) to confirm the exact deficiency.
• If your primary focus is manufacturing diagnostic kits: Source high‑purity raw materials—sensitized SRBCs, rabbit red blood cells, complement‑depleted matrix sera, and well‑characterized monoclonal antibodies—and validate every lot for functional and antigenic performance to ensure batch‑to‑batch reliability.

By understanding the distinct roles of functional hemolytic assays and quantitative component measurement, you create a diagnostic workflow that balances biological relevance with laboratory efficiency—ensuring no complement defect goes undetected.

Summary Table:

Building reliable complement assays requires ultra-pure, batch-consistent reagents. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. From high-affinity monoclonal antibodies to purified functional complement proteins and depleted matrices, we help you optimize assay sensitivity and stability. Ready to enhance your diagnostic formulations? Contact us today to consult with our technical team!